Summit Securities Group’s GSK GSK Stock Holding History

Summit Securities Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,100	Closed	-$427K	–	695
2024 Q2	$427K	Buy	+11,100	New	+$467K	0.08%	113
2022 Q2	–	Sell	-24,800	Closed	-$1.35M	–	1069
2022 Q1	$1.35M	Buy	24,800 +21,200	+589%	+$1.15M	0.15%	113
2021 Q4	$198K	Buy	3,600 +3,541	+6,002%	+$184K	0.01%	601
2021 Q3	$283K	Buy	+59	New	+$2.96K	0.02%	537
2021 Q1	–	Sell	-80	Closed	-$368K	–	657
2020 Q4	$368K	Hold	80	–	–	0.03%	416
2020 Q3	$376K	Buy	+80	New	+$4.01K	0.04%	252
2019 Q2	–	Sell	-43	Closed	-$226K	–	350
2019 Q1	$226K	Buy	+43	New	+$2.15K	0.04%	176
2017 Q2	–	Sell	-42	Closed	-$223K	–	299
2017 Q1	$223K	Buy	+42	New	+$2.13K	0.06%	263
2015 Q4	–	Sell	-18	Closed	-$8K	–	347
2015 Q3	$8K	Buy	+18	New	+$937	0.01%	265

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Summit Securities Group's GSK Position: Q2 2026 in Review

Summit Securities Group reduced its GSK (GSK) stake by 67% in Q2 2026, selling an estimated $10.6K and leaving 100 shares worth $5.24K. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.97M in Q4 2019. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Summit Securities Group held 100 shares of GSK worth $5.24K as of Q2 2026.
Summit Securities Group sold 200 GSK shares in Q2 2026, an estimated $10.6K.
GSK made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #967 holding.
Summit Securities Group first reported a position in GSK in Q2 2013 and has held it in 37 quarters since.
Summit Securities Group's GSK position peaked at $1.97M in Q4 2019.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.